LBA3_PR ?Randomized, non-inferiority

[1] LBA3_PR ?Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)? will be presented by Tae Won Kim during Proffered paper session 4 on Sunday, 19 November 2017, 14:30 to 16:00 (SGT) in Hall 405. Annals of Oncology, Volume 28, 2017 Supplement 10.
[2] Fuchs CS, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779?4786.
[3] Schmiegel W, et al. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 2013;24(6):1580?1587.
[4] Hamamoto Y, et al. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). Oncologist. 2014;19(11):1131?1132.